{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$3.68 vs. cons $3.66",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Net Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$17.0B vs. cons $16.81B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Skyrizi Q2 2026 Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$5.0B vs. cons $4.85B",
      "confidence": "HIGH"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EPS Guidance",
      "prediction": "BETTER",
      "answer": "guide ~$14.15-14.25 vs. cons $14.18 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Net Revenue Guidance",
      "prediction": "BETTER",
      "answer": "guide ~$67.5B vs. cons $67.3B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Skyrizi/Rinvoq combined sales guidance",
      "prediction": "BETTER",
      "answer": "guide ~$32.2B (Skyrizi ~$21.9B + Rinvoq ~$10.3B) vs. cons ~$31.6B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q3 2026 EPS Guidance (initial print)",
      "prediction": "UNKNOWN",
      "answer": "guide ~$3.70 vs. cons $3.68 (Q3 2026, pending IPR&D charges)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 1.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.3,
  "day5_path": "FADE",
  "day5_rationale": "Underlying beat-and-raise in immunology (Skyrizi/Rinvoq) likely drives an initial positive pop, but with the stock already up ~28% into the print and near/above sell-side targets, the reduced $3.57-3.61 guide optics and repeated IPR&D/milestone charges (Apogee dilutive to 2032) give analysts room to trim near-term EPS even while nudging long-term Skyrizi/Rinvoq estimates higher \u2014 a mixed revisions picture that tends to fade an initial pop as profit-taking sets in over the following days rather than sustain follow-through.",
  "day5_confidence": "LOW"
}